Profil
Eric Schlumpf is the founder of Stuart Therapeutics LLC, where he currently holds the titles of President, Chief Executive Officer, and Director.
The company was founded in 2018.
Postes actifs de Eric Schlumpf
| Sociétés | Poste | Début |
|---|---|---|
Stuart Therapeutics LLC
 Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Fondateur | 01/01/2018 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Stuart Therapeutics LLC
Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Commercial Services |
